Akari Therapeutics Plc (AKTX)
3.61
+0.11
(+3.14%)
USD |
NASDAQ |
May 19, 16:00
3.61
0.00 (0.00%)
After-Hours: 17:33
Akari Therapeutics Research and Development Expense (Quarterly) : 1.084M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| DBV Technologies SA | 31.31M |
| Cellectis SA | 23.09M |
| Biodexa Pharmaceuticals Plc | -- |
| NuCana Plc | 4.329M |
| Autolus Therapeutics Plc | 21.17M |